On the heels of a big earnings shortfall, the Japanese drugmaker's CEO is touting its cost-cutting programs and growth in emerging markets.
A report from the market research firm GlobalData finds that an unholy convergence of intellectual property worries, price controls and budget cuts is eroding earlier forecasts for emerging-market sales growth.
Don't look for a fabulous rebound in drug sales once the patent cliff is past. So says Roche COO Pascal Soriot, who expects a paltry 2% to 3% growth in the U.S. market and stagnant sales in Europe over the next three to 5 years.
Bayer CEO Marijn Dekkers is touting Xarelto 's multibillion-dollar prospects again. This time, though, it's just one of four prospective blockbusters drawing Dekkers' praise.
Bayer Healthcare said it expects Asia sales to grow to 11 billion euros by 2015, with 6 billion of that coming from the China region.
In the face of increasing scrutiny of its behavior in emerging markets, a global industry association has rolled out a strict new code of conduct.
Europe is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to
AstraZeneca ($AZN) CEO David Brennan (photo) talks emerging markets, external collaborations and townhall meetings in a Q&A with Roger Crockett. And, extending the current prefence for bolt-on
With leading generics makers moving into branded drugs as a hedge against slowing growth of the copycat industry, one might think the knockoff-drug business has transfigured into a tortoise, or
Now, it's Teva Pharmaceutical Industries ($TEVA) looking eastward for deals. The Israeli-based drugmaker figures the Asian generics market will be hopping over the next several years, with burgeoning